Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Stock Quote

Investor News and Events

  • Jul. 27, 2020 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has… Read more »

  • Jul. 10, 2020 Bioasis and Chiesi Group to Host Webcast on July 16, 2020

    GUILFORD, Conn., U.S.A. & PARMA, Italy–(Business Wire)– Bioasis Technologies, Inc. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases,… Read more »

  • Jul. 7, 2020 Bioasis Announces Stock Option Grants

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »

All Events and Presentations